Premier Medical Group

Elation Health and AAFP Innovation Lab Showcase Study Results of Value-Based Payment Models for Family Physicians at Annual FMX 2023

Retrieved on: 
Thursday, October 26, 2023

SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Elation Health, the clinical-first technology company powering innovation in primary care, announced today its plans at FMX 2023 in Chicago to discuss the highlights of a second study with the American Academy of Family Physicians (AAFP) Innovation Lab, which identifies key innovations that optimize the family medicine experience. The goal of the 2023 study, conducted with participation from 10 primary care practices of varying sizes, specifically identified barriers to and innovations required for mainstream adoption of value-based payment (VBP) models and its relationship to physician burnout.

Key Points: 
  • SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Elation Health , the clinical-first technology company powering innovation in primary care, announced today its plans at FMX 2023 in Chicago to discuss the highlights of a second study with the American Academy of Family Physicians (AAFP) Innovation Lab, which identifies key innovations that optimize the family medicine experience.
  • The Elation team, including Dr. Sara Pastoor and Nick Dealtry , will be on-site at FMX 2023 and available for attendees interested to learn more about how Elation supports family medicine and primary care physicians delivering the next generation of clinical experiences in value-based payment programs.
  • Event details: Elation Health is speaking and exhibiting at FMX 2023: Ignite - Fired up for Family Medicine's annual gathering.
  • Visit the Freedom Healthworks, Spruce, and Hint booths to collect all four stickers for a chance to win a prize.

Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director

Retrieved on: 
Wednesday, October 18, 2023

“Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.

Key Points: 
  • “Michael Rossi shares Y-mAbs’ belief that our future is bright as we continue to commercialize DANYELZA (naxitamab-gqgk) and build world-class capabilities working to develop and commercialize new innovative treatments that improve the lives of patients with cancer.
  • “We are extremely grateful for Thomas’s successful leadership and dedication as Interim CEO.
  • We look forward to Thomas’s continued leadership in his new role as Vice Chairman of the Board of Directors and Chief Business Officer of Y-mAbs.”
    Mr. Rossi said, “I have long admired Y-mAbs as a leader in the development of transformative cancer therapies.
  • Y-mAbs is a pioneer in pretargeted radioimmunotherapy with its SADA Technology and diverse pipeline of promising SADA programs, and a science-driven, patient-first culture.

PATHBUILDERS REACHES MILESTONE OF 3,000 ACHIEVA GRADUATES WITH 34TH CLASS

Retrieved on: 
Wednesday, May 31, 2023

ATLANTA, May 31, 2023 /PRNewswire/ -- Pathbuilders surpasses a new milestone graduating over 3,000 women from its flagship mentoring program, Achieva®.

Key Points: 
  • ATLANTA, May 31, 2023 /PRNewswire/ -- Pathbuilders surpasses a new milestone graduating over 3,000 women from its flagship mentoring program, Achieva®.
  • "Reaching 3,000 Achieva graduates reflects our ongoing commitment to moving women forward by transforming these leaders and creating cultures where they can thrive."
  • The company's most recent milestone was achieved with the graduation of 80 women in April from the 12-month Achieva® program.
  • Originally known as Georgia 100®, Achieva is one of the Pathbuilders programs designed for the four key stages in a woman's career.

Boost Medical Group Selects Trevelino/Keller to Launch and Scale New Brand

Retrieved on: 
Thursday, February 16, 2023

Trevelino/Keller will support Boost Medical Group with a 360-degree growth marketing and PR approach, encompassing branding, website development, lead generation and earned media.

Key Points: 
  • Trevelino/Keller will support Boost Medical Group with a 360-degree growth marketing and PR approach, encompassing branding, website development, lead generation and earned media.
  • “Our goal at Boost Medical is to provide attorneys and their clients with a complete and efficient solution that can make a difference for case outcomes,” stated Bob Hopta, managing partner at Boost Medical Group.
  • “Boost Medical Group is aiming to solve a problem that no other has tried – or been successful – tackling,” noted Dean Trevelino, principal at Trevelino/Keller.
  • We look forward to supporting Boost Medical in what’s ahead, as they’re poised to disrupt the personal injury space.”
    Trevelino/Keller brings nearly 20 years of brand reputation, media strategy, digital expertise and creative services to its partnership with Boost Medical Group.

Premier Medical Laboratory Services Hires Bioinformatics Expert, Dr. Daniel Hughes

Retrieved on: 
Tuesday, February 15, 2022

GREENVILLE, S.C., Feb. 15, 2022 /PRNewswire/ --Dr. Daniel Hughes, M2Gen's former Director of Cancer Knowledge Base and Pharma Services, has joined Premier Medical Laboratory Services (PMLS) as the Director of Bioinformatics.

Key Points: 
  • GREENVILLE, S.C., Feb. 15, 2022 /PRNewswire/ --Dr. Daniel Hughes, M2Gen's former Director of Cancer Knowledge Base and Pharma Services, has joined Premier Medical Laboratory Services (PMLS) as the Director of Bioinformatics.
  • "We are completely honored to have Daniel join the team," said Kevin Murdock, CEO of Premier Medical Laboratory Services.
  • Now, he joins Premier Medical Laboratory Services as the Director of Bioinformatics.
  • Premier Medical Laboratory Services is fully certified by all major accrediting organizations including Clinical Laboratory Improvement Amendments (CLIA) and COLA.

Senior Management Increases Shareholdings in EC Healthcare With Strong Confidence in the Group's Future Development

Retrieved on: 
Monday, January 17, 2022

As a result, Mr. Tang holds approximately 61.17% of the issued share capital of the Company.

Key Points: 
  • As a result, Mr. Tang holds approximately 61.17% of the issued share capital of the Company.
  • Besides, the Group has already completed the previously announced Premier Medical Group (BVI) Limited and Bayley & Jackson Dental Surgeons Limited transactions.
  • EC Healthcare is always devoted to developing an enclosed healthcare ecosystem to provide one-stop health medical service to customers.
  • Looking forward, the Group remains confident about the long-term strong business growth momentum and will keep investing in IT, brand and service to consolidate the healthcare market."

EC Healthcare Acquires Specialty Medical Services Centers in Hong Kong

Retrieved on: 
Sunday, November 7, 2021

The Target Company has a long-standing history in providing medical services in Hong Kong.

Key Points: 
  • The Target Company has a long-standing history in providing medical services in Hong Kong.
  • As at the date of this announcement, the Target Company operates 5 medical centers in Hong Kong, providing a wide array of medical services covering 18 specialist disciplines and other allied health services, with over 30 full-time registered medical practitioners.
  • EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services.
  • The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.